Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples